All GLP-1 Journey Guides
342 hand-edited guides organized by topic, category, and medication. New guides go live every day.
Comparisons · 17 guides
Drug-by-drug comparisons and the pipeline
compare_arrowsDrug vs. drug (9)
Direct comparisons between the major GLP-1 brands.
The Best GLP-1 Medication for Weight Loss in 2026
Which GLP-1 is most effective for weight loss in 2026? Here's how Zepbound, Wegovy, Mounjaro, and Ozempic compare on results, dose, and access.
Read guidearrow_forwardGLP-1 Medications: How to Choose One You Can Stay On
GLP-1 medications differ less in what they do than in what they ask of you week to week. Compare dose steps, injection rhythm, and staying power.
Read guidearrow_forwardMounjaro vs Zepbound: Same Drug, Different Approval
Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly. Here's why the brand, label, and insurance coverage diverge.
Read guidearrow_forwardOral GLP-1 Medications: Every Approved Pill in 2026
Four oral GLP-1 pills are FDA approved: Rybelsus, Ozempic tablets, Wegovy tablets and Foundayo. Two molecules, two completely different daily routines.
Read guidearrow_forwardOzempic vs Mounjaro: Diabetes Drugs Compared
Ozempic and Mounjaro are both FDA-approved for type 2 diabetes. Here's how their mechanisms, A1C results, and weight effects differ.
Read guidearrow_forwardOzempic vs Wegovy: What's the Difference?
Ozempic and Wegovy share the same active drug, semaglutide. But the FDA approval, max dose, and price differ. Here's a clear side-by-side.
Read guidearrow_forwardRetatrutide vs Tirzepatide: What the Trials Show
Retatrutide vs tirzepatide on mechanism, trial weight loss, side effects and availability. The direct head-to-head trial has not reported yet.
Read guidearrow_forwardTirzepatide vs Semaglutide: Which GLP-1 Loses More Weight?
Tirzepatide and semaglutide are the two leading GLP-1 medications. Here's how their mechanisms, trial results, and side effects actually compare.
Read guidearrow_forwardWegovy vs Zepbound: Comparing the Two Weight-Loss Heavyweights
Wegovy and Zepbound are the two FDA-approved injections for chronic weight management. Here's how their results, doses, and trade-offs compare.
Read guidearrow_forwardscienceDrug spotlights (3)
Single-drug deep dives — Rybelsus, Saxenda, high-dose variants.
Rybelsus (Oral Semaglutide): How the Pill Form Works
Rybelsus is semaglutide in a daily tablet. Here's how it differs from Ozempic and Wegovy, why timing matters, and who it's actually for.
Read guidearrow_forwardSaxenda (Liraglutide): The Daily-Injection GLP-1 Still in Use
Saxenda is daily liraglutide 3.0 mg. Older than Wegovy but still prescribed. Here's where it fits, who it suits, and how the numbers compare.
Read guidearrow_forwardWegovy 7.2mg: What the Higher Dose Means
Wegovy's 7.2 mg high-dose option goes beyond the standard 2.4 mg. Here's who it's for, what trials showed, and how the titration step works.
Read guidearrow_forwardrocket_launchPipeline & future (4)
Drugs in development — Retatrutide, CagriSema, oral vs injectable, monthly.
CagriSema: Novo Nordisk's Next-Gen Combination
CagriSema pairs cagrilintide (an amylin analog) with semaglutide in one weekly injection. Here's the trial data so far and what to expect.
Read guidearrow_forwardThe Future of Monthly GLP-1s: What's in Development
Could a once-monthly GLP-1 replace weekly pens? Here's what's in development, what the science allows, and what to expect in the next few years.
Read guidearrow_forwardOral vs Injectable GLP-1s: Which Is Right for You?
Pill or pen? Oral GLP-1s like Rybelsus and injectables like Wegovy work differently. Here's how to think about efficacy, timing, and fit.
Read guidearrow_forwardRetatrutide Preview: The Triple-Agonist Coming Next
Retatrutide is Eli Lilly's GIP/GLP-1/glucagon triple agonist in Phase 3. Here's the trial data so far and what FDA approval could look like.
Read guidearrow_forwardfact_checkSources & research (1)
Where GLP-1 information comes from, and how far each source can be trusted.